Drug name - Qinlock
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8188113 | DECIPHERA PHARMS | Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
Jul, 2030
(7 years from now) | |
| US8461179 | DECIPHERA PHARMS | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
Jun, 2032
(9 years from now) | |
| CN101516379A | DECIPHERA PHARMS | Kinase Inhibitors For The Treatment Of Proliferative Diseases |
Jan, 2013
(9 years ago) | |
| CN101553232A | DECIPHERA PHARMS | Kinase Inhibitors Useful For The Treatment Of Proliferative Diseases |
Nov, 2013
(8 years ago) | |
| IN253776B | DECIPHERA PHARMS | Kinase Inhibitors Useful For The Treatment Of Proliferative Diseases |
Sep, 2027
(4 years from now) | |
| IN200900461P3 | DECIPHERA PHARMS | Kinase Inhibitirs Useful For The Treatment Of Proliferative Diseases |
Sep, 2027
(4 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| USRE48731 | DECIPHERA PHARMS | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
Jun, 2032
(9 years from now) | |
| US10966966 | DECIPHERA PHARMS | Methods of treating gastrointestinal stromal tumors |
Aug, 2040
(17 years from now) | |
| US11185535 | DECIPHERA PHARMS | Amorphous kinase inhibitor formulations and methods of use thereof |
Dec, 2040
(18 years from now) | |
Drugs and Companies using RIPRETINIB ingredient
Treatment: Treatment of gastrointestinal stromal tumor; Treatment of advanced gastrointestinal stromal tumor in patients having progressed from a first line administration of imatinib, a second line administration of sunitinib, and a third line administration of regorafenib
Dosage: TABLET;ORAL
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| 50MG | TABLET;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.